logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10775385 B1

PDFFull Text
Date of Patent:
Sep. 15, 2020

Filed:

Oct. 22, 2015

Treatment of autoimmune and inflammatory disorders with asymmetric tnf alpha trimers

Applicant:

Ucb Biopharma Sprl, Brussels, BE;

Inventors:

James Philip O'Connell, Slough Berkshire, GB;

John Robert Porter, Slough Berkshire, GB;

Alastair Lawson, Slough Berkshire, GB;

Boris Kroeplien, Slough Berkshire, GB;

Stephen Edward Rapecki, Slough Berkshire, GB;

Timothy John Norman, Slough Berkshire, GB;

Graham John Warrellow, Slough Berkshire, GB;

Tracy Lynn Arakaki, Slough Berkshire, GB;

Alex Buntin Burgin, Slough Berkshire, GB;

William Ross Pitt, Slough Berkshire, GB;

Mark Daniel Calmiano, Slough Berkshire, GB;

David Andreas Schubert, Slough Berkshire, GB;

Daniel John Lightwood, Slough Berkshire, GB;

Rebecca Jayne Wootton, Slough Berkshire, GB;

Assignee:

UCB BIOPHARMA SRL, Brussels, BE;

Attorney:

Medler Ferro Woodhouse & Mills PLLC

Primary Examiner:

Elly-Gerald Stoica

Int. Cl.
CPC ...
G01N 33/68 (2006.01); C07K 14/525 (2006.01); C07K 14/705 (2006.01); C07K 16/24 (2006.01); A61P 37/00 (2006.01); C07D 401/14 (2006.01); C07D 471/00 (2006.01); C07D 213/72 (2006.01); C07D 235/04 (2006.01); C07D 239/26 (2006.01); C07D 471/04 (2006.01); A61K 47/64 (2017.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
G01N 33/6845 (2013.01); A61K 47/6425 (2017.08); A61P 35/00 (2018.01); A61P 37/00 (2018.01); C07D 213/72 (2013.01); C07D 235/04 (2013.01); C07D 239/26 (2013.01); C07D 401/14 (2013.01); C07D 471/00 (2013.01); C07D 471/04 (2013.01); C07K 14/525 (2013.01); C07K 14/70575 (2013.01); C07K 16/241 (2013.01); G01N 33/6854 (2013.01); G01N 33/6863 (2013.01); C07K 2317/55 (2013.01); C07K 2317/92 (2013.01); G01N 2333/525 (2013.01); G01N 2500/02 (2013.01);
Abstract

A new, stable trimeric TNFα structure is disclosed with distorted symmetry which can bind to the TNFR1 receptor to attenuate signalling therefrom, which can be used in the treatment and/or prevention of diseases associated with the soluble TNFα/TNFR1 interaction. Membrane-bound TNFα is not affected in its ability to signal through TNFR2, and thus the new structure of TNFα may be used in therapies which do not significantly raise the risk of infection or malignancy.

Find Patent Forward Citations

Loading…